Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg (Q5114)

Name of the Procedure:

• Common Names: Injection Ogivri, Trastuzumab-dkst
• Technical Term: Administering Trastuzumab-dkst (Ogivri) for therapeutic use

Summary

This procedure involves the injection of Trastuzumab-dkst, a biosimilar to trastuzumab, commonly known as Ogivri. It is used primarily in the treatment of certain types of breast cancer.

Purpose

• Medical Conditions: Primarily addresses HER2-positive breast cancer.
• Goals: To inhibit cancer cell growth and improve patient survival rates.

Indications

• Symptoms: Uncontrolled growth of breast cancer cells.
• Patient Criteria: Patients diagnosed with HER2-positive breast cancer.

Preparation

• Pre-procedure Instructions: Patients may be advised to follow specific dietary or medication guidelines leading up to the procedure.
• Diagnostic Tests: Blood tests and imaging scans are typically required to determine eligibility.

Procedure Description

• Steps:
  1. Consent is obtained, and the patient’s medical history is reviewed.
  2. The injection site is cleaned.
  3. Trastuzumab-dkst is injected intravenously.
• Tools Used: Syringe, IV administration set.
• Anesthesia/Sedation: Typically, no anesthesia is required.

Duration

• Length of Procedure: Approximately 30-90 minutes, including preparation and administration.

Setting

• Location: Performed in hospitals, outpatient clinics, or specialized oncological centers.

Personnel

• Healthcare Professionals: Oncologists, registered nurses, and medical assistants.

Risks and Complications

• Common Risks: Site reactions, nausea, fatigue.
• Rare Complications: Severe allergic reactions, heart problems, infusion-related reactions.
• Management: Immediate medical intervention is available for complications.

Benefits

• Expected Benefits: Reduction in tumor size, slower cancer progression, and improved survival.
• Timeline: Benefits can typically be observed within several treatment cycles.

Recovery

• Post-Procedure Care: Patients should monitor the injection site for signs of infection and report any severe side effects.
• Recovery Time: Generally brief, with most patients returning to normal activities within a day. Follow-up appointments are necessary for ongoing assessment.

Alternatives

• Other Options: Other HER2-targeted therapies, traditional chemotherapy, radiation therapy, or surgical options.
• Pros and Cons: Alternatives may vary in effectiveness, side effects, and invasiveness compared to the described procedure.

Patient Experience

• During Procedure: Patients might feel a slight sting at the injection site and mild discomfort.
• After Procedure: Fatigue and minor site reactions are common, pain management and support measures are available to alleviate discomfort.

For more detailed information, consult with your healthcare provider to understand the full scope and implications of the procedure.